Is Clostridium sporogenes the same bacterium that causes botulism?

No. Clostridium sporogenes is a distinct, non-toxigenic species. It is closely related to Clostridium botulinum and, as strain PA 3679, is used precisely because it is a nontoxigenic stand-in for C. botulinum in food-industry heat-process validation — an established food-safety use that is separate from its role in gut tryptophan metabolism.

What is 3-IPA (indole-3-propionic acid)?

3-IPA, more fully 3-indolepropionic acid or indole-3-propionic acid (CAS 830-96-6), is a tryptophan-derived metabolite produced almost entirely by gut bacteria, chiefly Clostridium sporogenes. It circulates in blood, engages the pregnane X receptor and, in some contexts, the aryl hydrocarbon receptor, and is not to be confused with isopropyl alcohol, an IPA-style beer, or the International Phonetic Alphabet.

Does 3-IPA help with diabetes or blood sugar?

Higher circulating 3-IPA is associated with lower incident type 2 diabetes risk in a prospective human cohort (the Finnish Diabetes Prevention Study) and with better metabolic markers in other human studies — but this is observational association, not proof of cause and effect. Animal studies show IPA treatment improving glucose tolerance in mice. As of 2026-09-10, three registered clinical trials administer 3-IPA itself to humans (NCT06674018, completed pilot; NCT07105514, recruiting pilot follow-up; NCT07318129, recruiting in multiple sclerosis — all Glostrup University Hospital, Copenhagen), none of them testing a diabetes outcome. It should never be described as treating or curing diabetes.

Is taking more Clostridium sporogenes always a good idea?

Not established, and there is a real complicating finding: a 2024 mouse study found that direct oral Clostridium sporogenes supplementation increased fat mass, adipocyte size and serum triglycerides via enhanced energy absorption — the opposite direction from the metabolite-level associations. The organism and the molecule it makes are not interchangeable claims.

Gut Microbiology · Host-Microbiome Metabolite Science

Clostridium sporogenes is the protagonist. 3-Indolepropionic acid (3-IPA) is the biochemical bridge.

Published: 2026-09-05
Keywords: Clostridium sporogenes, 3-IPA, indole-3-propionic acid, fld gene cluster, pregnane X receptor, aryl hydrocarbon receptor, gut microbiome, diabetes evidence

A single gut bacterium — Clostridium sporogenes — runs a metabolic pathway that turns dietary tryptophan into 3-indolepropionic acid (3-IPA, also written indole-3-propionic acid or IPA), a molecule that circulates in blood, acts on host receptors, and is associated with better glucose regulation in at least one well-known human cohort. This page follows that chain end to end — organism, pathway, molecule, mechanism, evidence — and keeps every claim tied to the tier of evidence that actually supports it.

15-second answer

Clostridium sporogenes is a harmless, spore-forming gut bacterium (not the botulism organism, though closely related) that ferments amino acids and, in the process, converts tryptophan into 3-IPA. Higher blood 3-IPA is associated with lower type 2 diabetes risk and better metabolic markers in human studies — an association, not a demonstrated cause-and-effect, and three registered trials do give 3-IPA itself to people — NCT06674018 (a completed pilot), NCT07105514 (a recruiting follow-up pilot) and NCT07318129 (recruiting, in relapsing-remitting multiple sclerosis), all at Glostrup University Hospital, Copenhagen — but none of them tests the diabetes question. A 2024 mouse study also found that giving the bacterium itself increased fat gain — a reminder that the organism and the molecule are not the same claim.

Not what you might think: "3-IPA" here means 3-indolepropionic acid, a gut-microbial tryptophan metabolite (CAS 830-96-6) — not isopropyl alcohol, not an India Pale Ale beer style, not the International Phonetic Alphabet, and not Ingenuity Pathway Analysis software. All of those share the abbreviation "IPA"; none of them are this molecule. We lead with the full chemical name throughout for exactly this reason.

1. What Clostridium sporogenes is

A gut bacterium with a genuinely interesting double life — one identity in food science, a very different one in gut biochemistry.

Clostridium sporogenes is a Gram-positive, obligate anaerobic, spore-forming bacterium first described by Élie Metchnikoff in 1908. It lives in soil, marine and freshwater sediment, decaying organic matter, and the gut and faeces of humans and other animals. Like other clostridia, it survives harsh conditions by forming a tough, heat-resistant endospore — the swollen "drumstick" shape visible under the microscope when a cell sporulates, the same silhouette used in this site's own emblem.

Where it lives

Soil, marine and freshwater sediment, preserved meat and dairy, and the gut/faecal flora of humans and animals. It has also been studied as a colonizer of the low-oxygen interior of solid tumours — a separate research thread from the gut-metabolite story here.

What it is not

Not a pathogen in the ordinary sense — it does not produce a neurotoxin. It is, however, taxonomically close to Clostridium botulinum, which is exactly why the next section exists.

Not the bacterium behind botulism

Clostridium sporogenes is not Clostridium botulinum. The two species are close relatives, sit in the same fermentation family, and are sometimes hard to tell apart by classical microbiology — but C. sporogenes does not carry the genes for botulinum neurotoxin. That close-but-nontoxigenic relationship is itself put to work: a specific strain, PA 3679 (also catalogued as DSM 795 / NCIMB 10696), is the standard nontoxigenic surrogate used across the food industry to validate that a canning or thermal-processing step would have killed proteolytic C. botulinum — a real, decades-old, well-documented food-safety application. It is a genuinely separate identity from the gut-microbiome story on this page, and worth keeping distinct rather than blending the two into one impression of the organism.

Its metabolism: living by breaking amino acids apart

Many bacteria burn sugar. C. sporogenes is unusually good at a different trick: Stickland fermentation, a reductive process that pairs up amino acids and swaps electrons between them to generate ATP, with no sugar required. Recent work on the organism's core energy metabolism shows this reductive pathway extends to the aromatic amino acids — phenylalanine, tyrosine and tryptophan — which the cell processes not as a side reaction but as a genuine part of how it makes a living.³ That energy-harvesting talent is the same biology that, as the pathway below shows, produces 3-IPA as one of its outputs.

2. From tryptophan to 3-indolepropionic acid: the pathway

One dietary amino acid, four enzymatic steps, one circulating metabolite — and the genes have names.

The organism-to-metabolite link was first shown the hard way: germ-free mice have no detectable 3-IPA in their blood at all. Colonize those same mice with Clostridium sporogenes alone, and 3-IPA appears.² That single experiment is the foundational proof that this specific bacterium, on its own, is sufficient to produce the molecule in a living host.

The gene-by-gene route was mapped a few years later. A cluster of genes — named fld (locus tags CLOSPO_00309–00311 for the core steps) — carries tryptophan through a short reductive chain:

3-IPA indole-3-propionate

Scientific illustration — not experimental imagery. The fld pathway, redrawn in plain language from Dodd et al., 2017, Nature (locus tags CLOSPO_00309–00311).¹

Mutating fldC abolishes 3-IPA production entirely — direct genetic evidence that this cluster, not some side pathway, is responsible.¹ It is worth being plain about what "mapped" means here: the primary paper's full gene-cluster detail sits partly behind a full-text access wall, so this description was cross-checked against a second, independent 2022 review of the same literature before publication on this page — the gene names and locus tags agree across both sources.

Not the only producer

The fld cluster is not unique to C. sporogenes. It recurs, largely intact, in a small set of related anaerobes:

Table 1. Organisms confirmed to carry the fld-type pathway or a related one — not an exhaustive list of every gut microbe ever proposed as an IPA producer.
Organism	Relationship to 3-IPA	Note
Clostridium sporogenes	Primary, best-characterised producer	The organism this site is built around
Clostridium botulinum	Carries a syntenic fld cluster	Toxigenic relative — a different organism from PA 3679's food-safety surrogate role
Clostridium cadaveris	Carries a syntenic fld cluster	Less-studied relative
Peptostreptococcus anaerobius	Carries a syntenic fld cluster	A different genus entirely
Peptostreptococcus spp. (incl. P. russellii)	Makes the related but distinct indoleacrylic acid, not 3-IPA	A genuinely different molecule from the same aromatic-amino-acid neighbourhood^†

† Indoleacrylic acid, from Peptostreptococcus species, is chemically adjacent to 3-IPA but is a different compound with its own separate literature (Wlodarska et al., 2017, Cell Host & Microbe) — it is not interchangeable with 3-IPA and is mentioned here only to prevent that mix-up.

One secondary-source synthesis this site's own research encountered attributed 3-IPA production more broadly to Lactobacillus reuteri and "Akkermansia" as well — that attribution does not appear in the primary fld-pathway literature reviewed for this page, so it is flagged here as uncorroborated rather than repeated as settled fact. We would rather leave a gap visible than smooth it over.

3. What 3-indolepropionic acid is

The molecule, precisely — before the mechanisms and the evidence.

Identity

3-Indolepropionic acid (indole-3-propionic acid; 3-IPA; IPA) — CAS 830-96-6. An indole ring with a three-carbon propionic-acid side chain, molecular formula C₃₁₁H₁₁NO₂. A single gut-microbial step downstream of tryptophan via the pathway above.

Where it is found

Almost entirely microbiome-dependent: production in mice was shown to be completely dependent on the presence of gut microflora, and could be re-established by colonizing germ-free mice with Clostridium sporogenes alone.²

3-IPA also has a proposed chemistry role independent of any receptor: it is described in the antioxidant literature as a potent hydroxyl-radical scavenger, in some in-vitro comparisons said to rival or exceed melatonin, without forming pro-oxidant byproducts of its own.^‡ That characterisation belongs to chemistry/neuroscience in-vitro work — it is interesting, but it is not itself a diabetes finding, and this page keeps it in its own lane rather than folding it into the metabolic-evidence sections below.

4. How 3-IPA acts on the body — kept receptor-by-receptor, not blended

Two receptors show up in the 3-IPA literature. They show up in different papers, in different physiological contexts — never combined into a single diabetes-outcome study. That distinction matters enough to structure this whole section around it.

3-IPA STAGE 3 3-IPA engages PXR tight junctions draw together STAGE 4 a circulating metabolite

Scientific illustration — not experimental imagery. Germ-free mice have no detectable 3-IPA, and colonising them with Clostridium sporogenes alone restores it (Wikoff WR et al., PNAS 2009;106(10):3698–703, PMID 19234110). The fld pathway carries tryptophan through indole-3-pyruvate, indole-3-lactate and indole-3-acrylate to 3-indolepropionate (Dodd D et al., Nature 2017;551(7682):648–652, PMID 29168502). 3-IPA regulates gastrointestinal barrier function through the xenobiotic sensor PXR (Venkatesh M et al., Immunity 2014;41(2):296–310, PMID 25065623). AhR is deliberately not drawn here — this site keeps PXR and AhR separate because their published contexts differ, and one animation blending them would undo that distinction in a single frame. Figure by Bogdan Dicoias for Panacea Bio Chem.

The pregnane X receptor (PXR) — the gut-barrier story

Mechanistic In PXR-knockout mice (Nr1i2^-/- and Nr1i2^-/-Tlr4^-/-), 3-IPA binds and activates PXR, downregulates enterocyte TNF-alpha, and upregulates junctional-protein expression — strengthening the gut's barrier function.⁴ This paper names only PXR. It says nothing about AhR, and nothing about diabetes.

The aryl hydrocarbon receptor (AhR) — different papers, different contexts

MechanisticAnimal In a mouse sepsis model, 3-IPA "partially activates" AhR to promote macrophage phagocytosis and reduce septic injury.⁵ In vitro Separately, in breast-cancer cell lines, 3-IPA activates both AhR and PXR together to produce cytostatic, oxidative-stress effects — a cancer-biology in-vitro finding, not a metabolic one.⁶

Why this separation matters No paper reviewed for this site combines PXR and AhR engagement with a diabetes or glucose-regulation outcome in one study. The receptor mechanisms are real and independently confirmed; the diabetes-cohort evidence (next section) does not itself report receptor data. The mechanistic bridge from receptor to blood-sugar outcome is plausible, not yet demonstrated end-to-end — and this page says so rather than implying otherwise by writing one confident sentence that quietly merges three different studies.

5. The evidence on glucose regulation, insulin sensitivity and diabetes

Six tiers, kept strictly separate, every one of them sourced. The full ledger — every citation, every exact finding — lives on its own page: the complete Evidence Ledger →. Here is the shape of it.

Table 2. The six-tier evidence structure this site uses for every claim about 3-IPA and metabolic health.
Tier	What it means	Headline finding here
Mechanistic	A receptor or pathway is shown to be engaged	PXR (Venkatesh 2014); AhR (Huang 2022)
In vitro	Cell-culture demonstration	AhR+PXR cytostatic effect in breast-cancer cells (Sari 2020)
Animal	Effect shown in a live animal model	Improved glucose tolerance & Akt phosphorylation in mice (Ballanti 2024)
Observational human	Human association, not manipulated	Higher serum 3-IPA → lower incident type 2 diabetes — Finnish Diabetes Prevention Study cohort (de Mello et al., 2017)⁷
Interventional human	A variable was actually manipulated in people	A fried-meat feeding trial lowered fecal 3-IPA alongside insulin-sensitivity changes — diet was manipulated, not 3-IPA itself (Gao et al., 2021)⁸
Unproven hypothesis	Plausible, not yet tested this way	3-IPA (or a C. sporogenes probiotic) as a future preventive strategy for type 2 diabetes

Stated plainly As of 2026-09-10, ClinicalTrials.gov lists three registered trials that administer 3-indolepropionic acid itself to human participants — NCT06674018 (a completed pilot, healthy volunteers), NCT07105514 (a recruiting pilot follow-up) and NCT07318129 (recruiting, relapsing-remitting multiple sclerosis), all from the iPROACT programme at Glostrup University Hospital, Copenhagen. None of the three tests a diabetes or glucose-regulation endpoint — that specific trial does not exist yet. The Finnish cohort finding is a genuine, prospective, human association — not proof that raising 3-IPA causes better blood sugar control. Whether low 3-IPA is a cause of worse metabolic health or simply a marker of a fibre-fermenting, tryptophan-processing gut ecosystem that itself tracks with a healthier diet is an open question — see the full Evidence Ledger for the trial-status search record and the causal-direction discussion.

6. Adjacent metabolic evidence — liver, heart, inflammation

Related findings, clearly boundaried from the diabetes evidence above — never merged into one "metabolic health" sentence.

Liver

Animal 3-IPA inhibits gut dysbiosis and endotoxin leakage, reducing steatohepatitis in rats.⁹ Observational human Lower circulating 3-IPA associates with greater hepatic fibrosis in a human cohort, alongside supporting in-vitro hepatic-stellate-cell data.¹⁰

Cardiovascular

Observational human Lower 3-IPA associates with coronary artery disease / atherosclerotic cardiovascular disease, a finding replicated in an independent human cohort. Animal Dietary 3-IPA supplementation reduced atherosclerotic plaque in ApoE-knockout mice via reverse cholesterol transport.¹¹

Inflammation

Animal Clostridium sporogenes-derived metabolites (the mixture, not 3-IPA alone) protected mice against colonic inflammation.¹² This is a distinct endpoint from the adipogenesis finding in the next section — same organism, different outcome, different model.

7. Is more Clostridium sporogenes always better?

No — and this is the single most important distinction on this site.

The organism-vs-metabolite contradiction Animal A 2024 study found that giving mice Clostridium sporogenes itself — the live organism, six weeks, oral supplementation — increased body weight, fat mass, adipocyte size, serum triglycerides and hepatic lipogenesis gene expression, via enhanced intestinal energy absorption, despite unchanged feed intake.¹³ That is the opposite direction from the metabolite-level findings above.

Giving mice or associating humans with the molecule the bacterium makes points one way; giving mice the bacterium itself points, in this one study, the other way. These are not the same claim, and the honest reading is that the relationship between the organism and human metabolic health is genuinely unresolved — not a flattering story this site is choosing to soften. The full skeptic-graph treatment of this tension, the trial-status ledger, and an honest buyer-intent answer live on their own page: Is more Clostridium sporogenes always better? →

8. Panacea Bio Chem's relationship to this page

3-ipa.com is not a Panacea Bio Chem product page. No Panacea technology, formulation or programme produces, contains or delivers 3-IPA, and none is claimed to. This site exists because Panacea Bio Chem's estate already researches gut-microbiome-adjacent and metabolic-health science, and because the operator's own standard for this site — separate the evidence tiers, disclose the contradicting finding, never upgrade an association into a cure claim — is the same discipline Panacea Bio Chem applies to its own formulation science elsewhere. Nothing here is medical advice.

Bogdan Dicoias — Biochemist, Director of Panacea Bio Chem

"The interesting thing about Clostridium sporogenes is that it refuses to be a simple story. It makes a molecule that looks genuinely useful, and in the same breath a 2024 study shows the organism itself can do the opposite. That is exactly the kind of finding worth publishing plainly, not editing out."

Bogdan Dicoias — Biochemist · Panacea Bio Chem Ltd

Frequently asked

What is Clostridium sporogenes?
A Gram-positive, spore-forming, obligate anaerobic gut bacterium, closely related to but distinct from Clostridium botulinum. It ferments amino acids reductively and, in doing so, converts tryptophan into 3-indolepropionic acid (3-IPA).

Is Clostridium sporogenes the same as the botulism bacterium?
No. It is a separate, non-toxigenic species, and strain PA 3679 is the standard food-safety surrogate for validating that heat processing would kill C. botulinum — a genuinely distinct use of the organism from its gut-metabolite role.

What is 3-IPA?
3-Indolepropionic acid (indole-3-propionic acid, CAS 830-96-6), a tryptophan-derived metabolite made almost exclusively by gut bacteria, chiefly Clostridium sporogenes. Not to be confused with isopropyl alcohol, an IPA beer, or the phonetic alphabet.

Does 3-IPA help with diabetes?
Higher blood 3-IPA is associated with lower type 2 diabetes risk in a prospective human cohort (the Finnish Diabetes Prevention Study) and with favourable animal-model findings — association and mechanism, not a demonstrated human treatment effect. As of 2026-09-10, three registered trials do give 3-IPA itself to people — NCT06674018 (completed pilot), NCT07105514 (recruiting pilot follow-up) and NCT07318129 (recruiting, multiple sclerosis), all at Glostrup University Hospital, Copenhagen — but none for this purpose: no registered trial tests 3-IPA against a diabetes or blood-sugar outcome.

Is taking more Clostridium sporogenes always beneficial?
Not established. A 2024 mouse study found that direct oral supplementation with the organism increased fat mass and triglycerides — the opposite direction from the metabolite-level evidence. See the dedicated page for the full treatment.

Trending in the field

References & further reading

Dodd D, Spitzer MH, Van Treuren W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature, 2017. PubMed 29168502.
Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. PNAS, 2009. PubMed 19234110.
Liu Y, et al. Clostridium sporogenes uses reductive Stickland metabolism in the gut to generate ATP and produce circulating metabolites. Nature Microbiology, 2022. PubMed 35505245.
Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity, 2014. PubMed 25065623.
Huang ZB, et al. Gut microbiota-derived indole 3-propionic acid partially activates aryl hydrocarbon receptor to promote macrophage phagocytosis. Frontiers in Cellular and Infection Microbiology, 2022. PubMed 36299625.
Sari Z, Miko E, Kovacs T, et al. Indolepropionic acid, a metabolite of the microbiome, has cytostatic properties in breast cancer. Cancers, 2020. PubMed 32854297.
de Mello VD, Paananen J, Lindstrom J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Scientific Reports, 2017. PubMed 28397877.
Gao J, et al. The association of fried meat consumption with the gut microbiota and fecal metabolites and its impact on insulin sensitivity. Diabetes Care, 2021. PubMed 34253560.
Zhao ZH, et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Experimental & Molecular Medicine, 2019. PubMed 31506421.
Sehgal R, et al. Indole-3-propionic acid, a gut-derived tryptophan metabolite, associates with hepatic fibrosis. Nutrients, 2021. PubMed 34684510.
Xue H, et al. Gut microbially produced indole-3-propionic acid inhibits atherosclerosis by promoting reverse cholesterol transport. Circulation Research, 2022. PubMed 35893593.
Krause FF, et al. Clostridium sporogenes-derived metabolites protect mice against colonic inflammation. Gut Microbes, 2024. PubMed 39397690.
Du L, et al. Clostridium sporogenes increases fat accumulation in mice by enhancing energy absorption and adipogenesis. Microbiology Spectrum, 2024. PubMed 38916334.
Owe-Larsson M, et al. (review synthesis) Indole-3-propionic acid as a neuroprotective antioxidant. Molecules, 2025. PubMed 40942152.

The complete tiered citation list, including every PMID, exact quoted findings and the trial-status search record, is on the Evidence Ledger page. Last evidence search: 2026-09-05 (clinical-trial registry re-checked and the trial record corrected 2026-09-10).